Patient-Derived Xenograft / PDX Model Market
According to Intent Market Research, the Patient-Derived Xenograft / PDX Model Market is expected to grow from USD 356 million in 2023-e at a CAGR of 13.7% to touch USD 818 million by 2030. The patient-derived xenograft model market is dominated by key players such as Wuxi Apptec, Charles River Laboratories, The Jackson Laboratory, Taconic Biosciences, Urosphere, Xentech, Inotiv, and Oncodesign Precision Medicine.